Valuation: Nanobiotix

Market Cap 1.42B 1.56B 1.31B 1.18B 2.23B 148B 2.31B 15.75B 6.25B 78.79B 5.87B 5.75B 250B P/E 2026 *
-44.9x
P/E 2027 * -112x
Enterprise Value 1.43B 1.58B 1.33B 1.2B 2.25B 149B 2.33B 15.93B 6.32B 79.69B 5.94B 5.81B 253B EV / Sales 2026 *
48.7x
EV / Sales 2027 * 33.6x
Free-Float
84.75%
Yield 2026 *
-
Yield 2027 * -
1 day-3.93%
1 week+3.33%
Current month-0.78%
1 month+41.34%
3 months-13.62%
6 months-36.33%
Current year+43.08%
1 week 27.28
Extreme 27.28
29.78
1 month 18.46
Extreme 18.46
31.32
Current year 16.66
Extreme 16.66
47.66
1 year 16.52
Extreme 16.52
47.66
3 years 2.62
Extreme 2.62
47.66
5 years 1.61
Extreme 1.612
47.66
10 years 1.61
Extreme 1.612
47.66
Manager TitleAgeSince
Chief Executive Officer 55 15/11/2009
Director of Finance/CFO 59 30/09/2026
Chief Tech/Sci/R&D Officer 68 04/09/2023
Director TitleAgeSince
Director/Board Member 76 22/06/2011
Director/Board Member 65 31/12/2013
Director/Board Member 57 17/06/2014
Date Insider Type Main position Quantity % Market Cap. Importance
17/07/26 Buy

Chairman

598 0.0012%
17/07/26 Buy

Chairman

598 0.0012%
16/07/26 Buy

Chairman

6,114 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
-3.93%+3.33%+53.47%+404.52% 1.56B
-2.69%-0.48%+53.97%+66.82% 66.33B
-0.92%+7.67%+12.64%+93.22% 60.62B
0.00%+0.39%+22.34%+89.58% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
-2.32%-2.24%+76.50%+56.02% 32.22B
+2.62%+5.90%-37.29%+386.59% 26.58B
Average -0.95%+0.38%+38.46%+199.36% 41B
Weighted average by Cap. -0.84%+0.21%+36.69%+153.20%

Financials

2026 *2027 *
Net sales 29.44M 32.49M 27.23M 24.57M 46.3M 3.06B 47.93M 327M 130M 1.64B 122M 119M 5.19B 44.36M 48.96M 41.03M 37.02M 69.77M 4.62B 72.23M 493M 195M 2.47B 184M 180M 7.83B
Net income -28.75M -31.73M -26.6M -24M -45.22M -2.99B -46.81M -319M -127M -1.6B -119M -117M -5.07B 604K 666K 558K 504K 949K 62.81M 983K 6.71M 2.66M 33.55M 2.5M 2.45M 107M
Net Debt 16.09M 17.75M 14.88M 13.43M 25.3M 1.67B 26.19M 179M 70.88M 894M 66.63M 65.21M 2.84B 74.7M 82.43M 69.09M 62.34M 117M 7.77B 122M 830M 329M 4.15B 309M 303M 13.18B
Projected Income Statement - Annual - Nanobiotix
Logo Nanobiotix
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: JNJ-1900 (NBTXR3), which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under.
Employees
98
Date Price Change Volume
13/11/26 €27.90 -3.93% 96,694
12/11/26 €29.04 -0.14% 110,816
11/11/26 €29.08 +0.21% 105,012
10/11/26 €29.02 +1.82% 91,916
09/11/26 €28.50 +5.56% 108,403
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Nanobiotix
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
27.90EUR
Average target price
52.20EUR
Spread / Average Target
+87.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Nanobiotix
  1. Stock Market
  2. Stocks
  3. NANO Stock